Scarica l'app Stockscreener
9.895
1.14%
0.115
Precedente Chiudi:
$9.78
Aprire:
$9.82
Volume 24 ore:
638.20K
Relative Volume:
0.40
Capitalizzazione di mercato:
$3.11B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-14.54
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
-3.88%
1M Prestazione:
+1.55%
6M Prestazione:
+37.76%
1 anno Prestazione:
+13.69%
Intervallo 1D:
$9.75
$9.98
Intervallo di 1 settimana:
$9.56
$10.30
Portata 52W:
$6.685
$10.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
9.895 | 3.05B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
143.80 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.92 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.205 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.77 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
429.40 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals Highlights Innovation and Access to Medication to Treat Patients - WJLA
What analyst consensus says on Amneal Pharmaceuticals Inc. stockFed Meeting & Risk Managed Investment Entry Signals - newser.com
What moving averages say about Amneal Pharmaceuticals Inc.2025 Earnings Surprises & Daily Stock Trend Reports - newser.com
Why Amneal Pharmaceuticals Inc. stock is considered a top pickMarket Movement Recap & High Accuracy Buy Signal Tips - newser.com
How to manage a losing position in Amneal Pharmaceuticals Inc.2025 Retail Activity & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. see short term momentumWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
What MACD and RSI say about Amneal Pharmaceuticals Inc.Oil Prices & Accurate Technical Buy Alerts - newser.com
Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - Sahm
What to expect from Amneal Pharmaceuticals Inc. in the next 30 daysJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Will Amneal Pharmaceuticals Inc. stock benefit from automationVolume Spike & Safe Capital Growth Tips - newser.com
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis - MSN
Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga
Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
When is the best time to exit Amneal Pharmaceuticals Inc.July 2025 Outlook & Weekly High Return Stock Opportunities - newser.com
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why - Yahoo Finance
Technical analysis overview for Amneal Pharmaceuticals Inc. stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst Upgrades - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market - MSN
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - sharewise.com
Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025? - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Increases 6.9% This Week, Taking Three-year Gains to 420% - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Rating Update: Analysts See 18.48% Upside Potential - DirectorsTalk Interviews
Measuring Amneal Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Selloffs & Low Volatility Stock Recommendations - newser.com
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - Nasdaq
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab) - Business Wire
Applying Wyckoff theory to Amneal Pharmaceuticals Inc. stockJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Amneal Pharmaceuticals Inc. stockEarnings Trend Report & Expert Approved Momentum Ideas - newser.com
Is it time to cut losses on Amneal Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Using Python tools to backtest Amneal Pharmaceuticals Inc. strategies2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Sentiment analysis tools applied to Amneal Pharmaceuticals Inc.Portfolio Risk Summary & High Win Rate Trade Tips - newser.com
How to read the order book for Amneal Pharmaceuticals Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Will breakout in Amneal Pharmaceuticals Inc. lead to full recoveryGap Down & Comprehensive Market Scan Insights - newser.com
Amneal Pharmaceuticals Hits New 52-Week High of $10.43 - Markets Mojo
Is Amneal Pharmaceuticals Inc. stock cheap compared to fundamentalsEarnings Growth Report & Safe Entry Zone Identification - newser.com
Chart based exit strategy for Amneal Pharmaceuticals Inc.Market Volume Summary & Smart Investment Allocation Insights - newser.com
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):